Enhancing the Informativeness and Replicability of Imaging Genomics Studies

被引:35
作者
Carter, Cameron S. [1 ]
Bearden, Carrie E. [2 ]
Bullmore, Edward T. [3 ]
Geschwind, Daniel H. [4 ]
Glahn, David C. [2 ]
Gur, Raquel E. [5 ]
Meyer-Lindenberg, Andreas [6 ]
Weinberger, Daniel R. [7 ]
机构
[1] Univ Calif Davis, 4701 X St, Sacramento, CA 95816 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] Univ Cambridge, Cambridge, England
[4] Yale Univ, New Haven, CT USA
[5] Univ Penn, Philadelphia, PA 19104 USA
[6] Heidelberg Univ, Cent Inst Mental Hlth, Mannheim, Germany
[7] Lieber Inst Brain Dev, Baltimore, MD USA
关键词
Clinical confounds; Imaging genomics; Multiple comparisons; Replication; Sample size; Statistical power; NEUROSCIENCE TREATMENT RESEARCH; TEST-RETEST RELIABILITY; INTERMEDIATE-PHENOTYPE; IMPROVE COGNITION; HUMAN HIPPOCAMPAL; BIPOLAR DISORDER; SCHIZOPHRENIA; RISK; VARIANTS; ASSOCIATION;
D O I
10.1016/j.biopsych.2016.08.019
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Imaging genomics is a new field of investigation that seeks to gain insights into the impact of human genetic variation on the structure, chemistry, and function of neural systems in health and disease. Because publications in this field have increased over the past decade, increasing concerns have been raised about false-positive results entering the literature. Here, we provide an overview of the field of imaging genomic and genetic approaches and discuss factors related to research design and analysis that can enhance the informativeness and replicability of these studies. We conclude that imaging genetic studies can provide important insights into the role of human genetic variation on neural systems and circuits, both in the context of normal quantitative variation and in relation to neuropsychiatric disease. We also argue that demonstrating genetic association to imaging-derived traits is subject to the same constraints as any other genetic study, including stringent type I error control. Adequately powered studies are necessary; however, there are currently limited data available to allow precise estimates of effect sizes for candidate gene studies. Independent replication is necessary before a result can be considered definitive, and for studies with small sample sizes it is necessary before publication. Increased transparency of methods and enhanced data sharing will further enhance replicability.
引用
收藏
页码:157 / 164
页数:8
相关论文
共 53 条
[1]   Endophenotypes for psychiatric disorders: ready for primetime? [J].
Bearden, Carrie E. ;
Freimer, Nelson B. .
TRENDS IN GENETICS, 2006, 22 (06) :306-313
[2]   Power failure: why small sample size undermines the reliability of neuroscience [J].
Button, Katherine S. ;
Ioannidis, John P. A. ;
Mokrysz, Claire ;
Nosek, Brian A. ;
Flint, Jonathan ;
Robinson, Emma S. J. ;
Munafo, Marcus R. .
NATURE REVIEWS NEUROSCIENCE, 2013, 14 (05) :365-376
[3]   Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia [J].
Callicott, JH ;
Egan, MF ;
Mattay, VS ;
Bertolino, A ;
Bone, AD ;
Verchinksi, B ;
Weinberger, DR .
AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (04) :709-719
[4]   DISC1 and SLC12A2 interaction affects human hippocampal function and connectivity [J].
Callicott, Joseph H. ;
Feighery, Emer L. ;
Mattay, Venkata S. ;
White, Michael G. ;
Chen, Qiang ;
Baranger, David A. A. ;
Berman, Karen F. ;
Lu, Bai ;
Song, Hongjun ;
Ming, Guo-li ;
Weinberger, Daniel R. .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (07) :2961-2964
[5]   Optimizing the Design and Analysis of Clinical Functional Magnetic Resonance Imaging Research Studies [J].
Carter, Cameron S. ;
Heckers, Stephan ;
Nichols, Thomas ;
Pine, Daniel S. ;
Strother, Stephen .
BIOLOGICAL PSYCHIATRY, 2008, 64 (10) :842-849
[6]   Identifying cognitive mechanisms targeted for treatment development in schizophrenia: An overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia initiative [J].
Carter, Cameron S. ;
Barch, Deanna M. ;
Buchanan, Robert W. ;
Bullmore, Edward T. ;
Krystal, John H. ;
Cohen, Jonathan ;
Geyer, Mark ;
Green, Michael ;
Nuechterlein, Keith H. ;
Robbins, Trevor ;
Silverstein, Steven ;
Smith, Edward E. ;
Strauss, Milton ;
Wykes, Til ;
Heinssen, Robert .
BIOLOGICAL PSYCHIATRY, 2008, 64 (01) :4-10
[7]   Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: The CNTRICS initiative [J].
Carter, Cameron S. ;
Barch, Deanna M. .
SCHIZOPHRENIA BULLETIN, 2007, 33 (05) :1131-1137
[8]  
Carter Cameron S, 2016, Biol Psychiatry Cogn Neurosci Neuroimaging, V1, P99, DOI 10.1016/j.bpsc.2016.01.005
[9]   Imaging Biomarkers for Treatment Development for Impaired Cognition: Report of the Sixth CNTRICS Meeting: Biomarkers Recommended for Further Development [J].
Carter, Cameron S. ;
Barch, Deanna M. .
SCHIZOPHRENIA BULLETIN, 2012, 38 (01) :26-33
[10]   Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: Developing Imaging Biomarkers to Enhance Treatment Development for Schizophrenia and Related Disorders [J].
Carter, Cameron S. ;
Barch, Deanna M. ;
Bullmore, Edward T. ;
Breiling, James ;
Buchanan, Robert W. ;
Butler, Pamela ;
Cohen, Jonathan D. ;
Geyer, Mark ;
Gollub, Randy ;
Green, Michael F. ;
Jaeger, Judith ;
Krystal, John H. ;
Moore, Holly ;
Nuechterlein, Keith ;
Robbins, Trevor ;
Silverstein, Steven ;
Smith, Edward E. ;
Strauss, Milton ;
Wykes, Til .
BIOLOGICAL PSYCHIATRY, 2011, 70 (01) :7-12